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Abstract
Background: Fully functional HIV-1-specific CD8 and CD4 effector T-cell responses are vital to the
containment of viral activity and disease progression. These responses are lacking in HIV-1-infected
patients with progressive disease. We attempted to augment fully functional HIV-1-specific CD8 and CD4
effector T-cell responses in patients with advanced chronic HIV-1 infection.
Design: Chronically infected patients with low CD4 counts T-cell counts who commenced antiretroviral
therapy (ART) were subsequently treated with combined interleukin-2 and therapeutic vaccination.
Methods: Thirty six anti-retroviral naive patients were recruited and initiated on combination ART for
17 weeks before randomization to: A) ongoing ART alone; B) ART with IL-2 twice daily for 5 days every
four weeks starting at week 17 for 3 cycles; C) ART with IL-2 as in group B and Remune HIV-1 vaccine
administered once every 3 months, starting at week 17; and D) ART with Remune vaccine as in group C.
Patients were studied for 65 weeks following commencement of ART, with an additional prior 6 week
lead-in observation period. CD4 and CD8 T-cell counts, evaluations of HIV-1 RNA levels and proliferative
responses to recall and HIV-1 antigens were complemented with assessment of IL-4-secretion alongside
quantification of anti-HIV-1 CD8 T-cell responses and neutralizing antibody titres.
Results: Neither IL-2 nor Remune™ vaccination induced sustained HIV-1-specific T-cell responses.
However, we report an inverse relationship between HIV-1-specific proliferative responses and IL-4
production which continuously increased in patients receiving immunotherapy, but not patients receiving
ART alone.
Conclusion: Induction of HIV-1-specific cell-mediated responses is a major challenge in chronically HIV-
1-infected patients even when combining immunisation with IL-2 therapy. An antigen-specific IL-4-
associated suppressive response may play a role in attenuating HIV-specific responses.
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Background
Immune recovery subsequent to antiretroviral therapy
(ART) often appears to be partial and does not comprise
the HIV-1-specific CD4 or CD8 T-cell proliferative and IL-
2-producing responses that are associated with protection
from disease progression [1-5]. These potentially protec-
tive HIV-1-specific T-cell responses [6-9], become dys-
functional and exhausted with progressing disease. A
number of approaches attempt modulation of cell-medi-
ated responses, including therapeutic immunisation
[2,10-12]. Remune™ is a whole, gp120-depleted, inacti-
vated, HIV-1 immunogen in incomplete Freund's adju-
vant (IFA) prepared from the recombinant primary isolate
HZ-321 [13] (clade A envelope, clade G gag). Clinical tri-
als of intramuscular (I/M) Remune™ including one phase
III [14], have failed to demonstrate increases in disease-
free survival time despite Remune's™ induction of HIV-1-
specific CD4 T-cell responses [15]. Sub-group analysis
failed to demonstrate any consistent effects on viral loads
or CD4 counts [16]. Despite this, Remune™ may delay dis-
ease progression and reduce development of antiretroviral
resistance [17].
Sub-cutaneous (S/C) interleukin (IL)-2, administered
with ART, increases CD4 T-cell numbers [18-21] and
recall antigen-specific CD4 lymphocyte proliferation
[22,23]. However timing may be crucially important to
the induction of cell-mediated responses [24]. We have
previously shown that IL-2 administration subsequent to
immunization was associated with boosted responses to
the antigen in question, suggesting a therapeutic role for
IL-2 in enhancing proliferative T-cell responses in HIV-1
infection [2,25].
We investigated the ability of Remune™ and IL-2, com-
bined and separately, to induce HIV-1-specific CD4 and
CD8 T-cell responses in chronically HIV-1-infected
patients on ART in an observational, open-label, rand-
omized, pilot study. We also assessed antigen-specific IL-
4 release as this cytokine plays a role in balance and/or
suppression of cell-mediated responses [26,27], We report
here evaluation of specific T-cell proliferation, antigen-
specific IL-4 release, CD8 T-cell IFN-γ responses and neu-
tralizing antibody titres, in order to comprehensively
describe the specific immune response relevant to control
of viral replication.
Methods
Patients and Study Design
In this observational, phase I, pilot study conducted at
Chelsea and Westminster Hospital, London, 36 antiretro-
viral-naive patients were initiated on ART at week 0, which
was continued for the duration of the study. ART com-
prised 2 nucleoside analogues and one protease inhibitor
or non-nucleoside reverse transcriptase inhibitor. At week
17 patients were randomized to receive immunotherapy
with IL-2 and/or therapeutic immunisation with a gp120-
depleted whole inactivated HIV-1 immunogen. Sufficient
Remune™ was donated for use in 20 patients by Immune
Response Corporation (IRC), Carlsbad, CA, USA. Patients
were randomized at week 17 only if their viral load was
<50 copies ml/plasma and CD4 T-cell count was ≥ 300
cells/μl blood at week 16. Treatment groups for randomi-
zation were as follows: A) ART alone (n = 9); B) ART plus
IL-2 (Proleukin™) (n = 11); C) ART plus IL-2 and
Remune™ (n = 7); and D) ART plus Remune™ (n = 9). IL-
2 (5 × 106U) was administered S/C, twice daily, for 5 days
at weeks 17, 21 and 25. 100 μg Remune™ was adminis-
tered I/M at weeks 17, 29, 41 and 53. Laboratory analysis
was conducted at weeks- -6, -3 and 0 before ART, and
weeks 1, 2, 4, 8, 16, 17, 21, 25, 29, 41, 53 and at study
completion at week 65. The primary outcome was induc-
tion of positive changes in lymphocyte proliferative
responses to HIV-1 antigens. In addition to the main
study time points, a further sub-study of viral loads and
lymphocyte subset numbers was conducted in a sub-set of
patients (n = 15) receiving IL-2 in groups B and C on the
5th day of each IL-2 cycle, i.e. at weeks 18, 22 and 26. This
sub-study was initiated after the main study had begun
and included all patients receiving IL-2 in groups B and C
from the date of its inception. Appropriate regulatory
approval was granted by Riverside Ethics Committee and
patients gave written informed consent.
Separation of PBMCs
PBMC were separated from whole blood by density gradi-
ent centrifugation and cultured in RPMI-1640 with
NaCO3 (Sigma, Poole, UK) and 100 IU/ml penicillin, 100
μg/ml streptomycin and 2 mM L-glutamine supple-
mented with 10% human AB plasma (all Sigma).
Viral Load and Lymphocyte Subsets
Plasma viral load was measured using the Bayer HIV-1
RNA 3.0 assay (bDNA) (lower limit 50 copies/ml) (Bayer
Diagnostics, Newbury, UK). Whole blood lymphocytes
were counted with monoclonal antibodies to: CD3, CD4,
CD8, and CD45 (Tetra One, Beckman Coulter, High
Wycombe, UK) on an Epics XL-MCL flow cytometer
(Beckman Coulter).
Recall and HIV-1 antigens
Recombinant HIV-1 and recall antigens (Medical
Research Council Centralised Facility for AIDS Reagents,
National Institute for Biological Standards and Controls,
Potters Bar, UK) were used as described previously [2], at
a final concentration of 10 μg/ml. Remune™ and its native
p24 (IRC, Ca) were used at 3 μg/ml [28].Journal of Immune Based Therapies and Vaccines 2007, 5:6 http://www.jibtherapies.com/content/5/1/6
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Lymphocyte Proliferative Assays
Proliferation assays and supernatant collection for IL-4
assessment were conducted as previously described [2].
Stimulation indices (SI) for triplicates (standard error
<15%) were calculated as antigen-stimulated β-particle
counts per minute (cpm)/no antigen cpm. A positive
response was regarded as a SI >5.
Measurement of Cytokine Production
IL-4 bioassays were carried out as previously described [2]
using IL-4 (CT.h4S) dependent cell lines. Briefly, IL-4 was
measured in culture supernatants of HIV-1 antigen stimu-
lated proliferation assays. Proliferation of the IL-4-
dependent cell line CT.h4S was measured by incorpora-
tion of tritiated thymidine. Results are presented as IL-4
driven cpm.
Delayed hypersensitivity (DTH) tests to Remune™
In vivo delayed-type hypersensitivity (DTH) skin tests to
Remune™ antigen were performed to assess HIV-1-specific
cell-mediated immune responses as described elsewhere
[29] in all patients at weeks 17, 29 and 53.
HLA-typing
HLA haplotypes of patients were assessed by PCR-SSP
[30].
IFN-γ ELIspot assays
IFN-γ ELIspots were conducted as described previously
[31]. Briefly, 2.5 × 105 PBMC from individual patients
who had been tissue typed were cultured with or without
10 μg/ml of appropriate HLA-restricted peptides or PHA
(positive control) in 96-well anti-IFN-γ (Mabtech, Stock-
holm, Sweden) coated PVDF-backed plates (Millipore,
Watford, UK). After overnight incubation IFN-γ spot-
forming cells (SFC) were detected according to the manu-
facturer's instructions (Mabtech).
Neutralisation assays
Immunoglobulin (Ig)G was purified from patient and
HIV-1 negative plasma using the MAbTrap kit (Amersham
Biosciences, Little Chalfont, UK), and quantified by Pro-
tein Assay (Bio-Rad, Munich, Germany). Two-fold serial
dilutions of purified IgG, from 1 mg/ml, were incubated
with 100 focus forming units (FFU) of HIV-1SF162 for 1 hr
at 37°C and then plated onto NP2/CD4+/CCR5+ cells.
Infection was detected after 48 hrs by p24-immunostain-
ing, as detailed before [32]. The percentage reduction of
infection was calculated: 100 × (1-(mean FFU with patient
IgG)/(mean FFU with seronegative IgG at 1 mg/ml)).
Statistical Analysis
Changes in lymphocyte subsets and viral load between
week 0 and 16, weeks 0 and 65 and weeks 16 and 65, were
assessed using the Wilcoxon Signed Rank test. Prolifera-
tion and IL-4 data were assessed with repeated measures
analysis of variance using MIXED procedure in SAS statis-
tical software. For log-transformed antigen-specific prolif-
erative stimulation indices, between and within subject
weeks 0 to 17, weeks 17 to 65 and weeks 0 to 65, adjusted
separate slopes were estimated for each study arm with
95% confidence interval. Differences in overall viral load
from week 18–26, between groups B and C were assessed
using the Pearson Chi-squared test.
Results
Patient demographics
Fifty two anti-retroviral naïve patients were screened for
this study which was carried out at the Chelsea and West-
minster Hospital, London over a six year period. Of the
screened patients 16 dropped out prior to randomisation
at week 17. All the remaining 36 patients who were ran-
domised completed the study. The mean age of patients at
study entry was 38.75 years. There was one female patient
(2.78%) and 100% of patients were of white European
ethnicity.
Viral loads and CD4 T-cell counts
Median viral loads and CD4 T-cell counts for each group
are depicted in Figure 1. The median week 0 viral load for
all patients was 88,699 copies/ml plasma (range 50–
779,254). The median absolute CD4 T-cell count was 294
cells/μl whole blood (range 76–551). Nineteen of 36
patients (53%) had CD4 T-cell counts below 300 cells/μl
blood at pre-ART time points.
By week 17 the median viral load in all groups was less
than 50 copies. All patients, except 5 (one in Group A,
three in Group B, one in group D), maintained viral sup-
pression at the main study time points from week 17
onwards while receiving ongoing ART. One patient in
Group C (patient 11) elected to discontinue ART at week
47 causing subsequent rebound in viraemia. At week 17
the median CD4 T-cell count in each complete group was
as follows: Group A, 456 cells/μl (range 261–673) (Figure
1A); Group B, 377 cells/μl (range 81–742) (Figure 1B);
Group C, 468 cells/μl (range 306–680) (Figure 1C);
Group D, 337 cells/μl (range 289–702) (Figure 1D). IL-2-
induced increases in absolute CD4 T-cell counts are also
apparent in groups B and C. By week 65 these values were
602 cells/μl (range 300–918) for Group A, 731 cells/μl
(range 253–1025) for Group B, 619 cells/μl (range 358–
1404) for Group C and 505 cells/μl (range 345–768) for
Group D.
Lymphocyte proliferation to HIV-1 antigens
HIV-1-specific proliferative responses increased tran-
siently for many patients. Regression analysis of these
responses revealed no significant changes in group A (Fig.
2A). In group-B from week 0 to 65 a significant increase inJournal of Immune Based Therapies and Vaccines 2007, 5:6 http://www.jibtherapies.com/content/5/1/6
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the np24 response (p = 0.005) was observed (Fig. 2B). In
group C no increase in HIV-1-specific proliferative
responses were seen (Fig. 2C). Of note was an outstanding
response to Remune™ with an SI of 95 at week 65 for
patient 11 in this group (data not shown) coincident with
rebound viraemia (152,536 copies/ml) following self-
imposed ART discontinuation. In group D a positive
regression was seen in responses to Nef (p = 0.004) and
whole Remune™ antigen (p = 0.005) from week 0 to 65.
(Fig. 2D). The only response which significantly increased
between week 17 and 65 in any group was the p24
response in group D (p = 0.039). Patient 8 in this group
demonstrated a very large response to Remune™ (SI =
261) and np24 (SI = 144) at week 29 following break-
through of resistant virus at week 25 (6,315 copies/ml)
(data not shown). No other substantial increases in
responses occurred between week 17 and 65 for any group
or at any time point between the groups.
In vivo delayed type hypersensitivity reactions to 
Remune™
Induration size of hypersensitivity reactions to Remune™
did not become positive (>9 mm diameter) in any patient
at any of the time points tested (weeks 17, 29 and 53).
Lymphocyte proliferation to recall antigens
Baseline to week 16 T-cell responses have been described
in detail previously [1]. Regression analysis revealed sig-
nificant increases in recall responses in all groups between
week 0 and 65 (Fig. 2E–H), predominantly for the persist-
ent recall antigens: For group A (Figure 2E) responses to
CMV and Candida significantly increased (p = 0.027 and
p  = 0.006 respectively); for group B (Figure 2F) HSV
responses significantly increased (p  = 0.007), CMV
responses increased p  = 0.002 and Candida responses
increased (p = 0.0006); in group C (Figure 2G) CMV and
Candida responses increased (p = 0.002 and p = 0.007
respectively); in group D (Figure 2H) HSV and CMV
responses significantly increased (p  = 0.002 and p  =
0.001). Responses to transient antigens were less apparent.
In group A PPD and tetanus responses showed significant
positive regressions over the 65 weeks (p = 0.018 and p =
0.018 respectively); in group B only the PPD response
regression curve was significant (p = 0.044); and in group
C only the tetanus response was significant (p = 0.0003).
There were no significant differences in recall responses
between treatment groups.
HIV-1-specific IL-4 production
Antigen-specific IL-4 production may be associated with
suppression of proliferative responses and dampening of
inflammatory immune responses. Therefore we measured
Median absolute CD4 T-cell counts per μl of whole blood (closed diamonds) and median HIV-1 RNA viral load per ml of  plasma (open squares) with 1st and 3rd interquartile ranges over the entire study period for group A (A), group B (B), group C  (C), and group D (D) Figure 1
Median absolute CD4 T-cell counts per μl of whole blood (closed diamonds) and median HIV-1 RNA viral load per ml of 
plasma (open squares) with 1st and 3rd interquartile ranges over the entire study period for group A (A), group B (B), group C 
(C), and group D (D). A subset of patients were assessed for viral load and CD4 T-cell counts at day 5 of each IL-2 cycle in 
groups B and C. Results are shown for all patients. Elevations in viral loads occurred more often in viral loads of patients 
receiving ART and IL-2 without Remune™ (group B), than in patients receiving ART and IL-2 with Remune™ (group C).Journal of Immune Based Therapies and Vaccines 2007, 5:6 http://www.jibtherapies.com/content/5/1/6
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Mean HIV-1-specific lymphocyte proliferative responses (left-hand panel) with the times of IL-2 and Remune™ administration,  showing responses for group A (A), group B (B), group C (C) and group D (D) and mean recall-specific lymphocyte prolifera- tive responses (right-hand panel) with the times of IL-2 and Remune™ administration, for group A (E), group B (F), group C  (G) and group D (H) Figure 2
Mean HIV-1-specific lymphocyte proliferative responses (left-hand panel) with the times of IL-2 and Remune™ administration, 
showing responses for group A (A), group B (B), group C (C) and group D (D) and mean recall-specific lymphocyte prolifera-
tive responses (right-hand panel) with the times of IL-2 and Remune™ administration, for group A (E), group B (F), group C 
(G) and group D (H). The scale of HIV-1-specific responses is displayed as half the magnitude of that for recall responses.Journal of Immune Based Therapies and Vaccines 2007, 5:6 http://www.jibtherapies.com/content/5/1/6
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IL-4 production in proliferation assay culture superna-
tants in response stimulation with each HIV-1 antigen, as
previously described [1]. Significant increases in HIV-1-
specific IL-4 production from weeks 17 to 65 were
observed in response to p24 in group-B (p = 0.023), and
group C (p = 0.032) and in response to gp120 in group D
(p = 0.037) (Fig. 3A). HIV-1-specific IL-4 production did
not significantly increase in group A (data not shown).
We observed an apparent relationship between IL-4 pro-
duction and loss/lack of proliferation in 17 of 28 patients
tested, distributed evenly between groups, evident from
week 0 to 16 and week 17 to 65. Patient 11 (group C) is
shown as an example, where HIV-1-specific proliferative
responses to p24, gp120, nef and Remune™ are high at
week 29 (Fig. 3B) with absence of IL-4 (Fig. 3C), while at
week 41 IL-4 secretion increases as proliferation declines.
CD8 T-cell IFN-γ responses to HLA class I restricted 
peptides
Where possible we investigated CD8 T-cell IFN-γ produc-
tion in response to characterised HLA class I restricted
peptides (listed in Table 1), by ELISpot assay using cryo-
preserved PBMCs. As reported previously [15] Remune™
did not induce increases in CD8 T-cell responses.
Although fluctuations occurred in CD8 T-cell IFN-γ
responses these were not sustained and could not be
attributed to ART or immunotherapy. Summary data is
presented from week 0, following ART alone at week 16
and at week 65 in Table 2. Assays in which responses were
not observed to the postive control, PHA, were considered
to have failed, as denoted by "F". Of note is the observa-
tion that no patient in groups B, C or D demonstrated an
increase in responses between week 16 and week 65.
Patient 11 is an exception, although this patient had high
baseline responses and by week 65 had discontinued ART
causing considerable rebound viraemia, concomitant
with strong HIV-1-specific lymphocyte proliferative
responses as detailed above.
Discordant viraemia between patients receiving IL-2 with 
or without Remune™
Secondary to the main study protocol, further viral load
and lymphocyte subset analysis was conducted at addi-
tional time points – week 18, week 22 and week 26 – for
a sub-group of 15 patients receiving IL-2 in groups B (n =
9) and C (n = 6) on the last day of each IL-2 cycle. Small,
transient elevations in HIV-1 RNA load were apparent on
12 occasions for 7 of 9 (78%) patients in group-B, and 2
of 6 patients (33%) in group-C. All these viral load eleva-
tions had spontaneously resolved by the next viral load
test 3 weeks later at weeks 21, 25 and 29. The difference in
occurrence of these viral load elevations remains evident
when comparing the median viral loads for all the
patients in groups B and C as shown in Fig. 1B and 1C.
The median viral load change (from 50 copies/ml) for the
patients who had day 5 viral load measurements in group
B were 23.5 copies/ml, 53 copies/ml and 0 copies/ml at
the end of each IL-2 cycle. In comparison the median
change in viral load for patients in group C who had day
5 viral load measurements was 0 at each time point.
Change in viral load was not significantly different when
comparing the sub-study patients in group B with those in
group C, at any of the 3 individual IL-2 day 5 time points.
However when taking all three day 5 time points together
for each group, comparison between the two groups
revealed a trend towards significance (p = 0.071, Pearson
Chi-Squared).
Neutralising antibody responses in discordant virologic 
responders
As Remune™ displays the transmembrane (gp41) enve-
lope antigen with strong neutralization epitopes [33-35],
it may prime neutralizing antibodies to new epitopes. We
tested the ability of plasma IgG from patients in Group C
who did not experience day 5 viral blips to neutralize HIV-
1SF162 at weeks 0, 16 and 65. There was no effect of immu-
notherapy or ART on virus neutralization (data not
shown).
Discussion
In this pilot study of combined immunotherapy with the
therapeutic HIV-1 vaccine Remune™ and subcutaneous IL-
2 in the context of ART, neither IL-2 nor Remune™ immu-
nisation confered any substantial benefits to the effect of
ART with regard to HIV-1-specific CD4 or CD8 T-cell
responses, or neutralising antibodies. For the majority of
these chronically HIV-1-infected patients responses to
HIV-1 antigens remained negligible and there was little
difference between the four immunotherapy arms. Possi-
ble reasons for this could be: the low CD4 T-cell counts of
these patients when ART was initiated resulting in pro-
tracted immunosuppression and/or clonal dysfunction; a
need for longer duration of ART before immunotherapeu-
tic intervention, thus allowing greater immune recovery;
the permanent depletion of HIV-1-specific CD4 T-cells by
direct HIV-1 infection; and/or the timing of IL-2 therapy
with immunisation which may have important conse-
quences for induction or suppression of induced
responses.
Previous Remune™ studies which induced proliferative
responses comprised patients with higher pre-ART mean
CD4 T-cell counts of 617 cells/μl [36] and 700 cells/μl
blood [15]. The mean in this study was 303 cells/μl. 53%
of these patients had CD4 nadirs below 300 cells/μl.
Immune reconstitution in patients who initiate ART with
low CD4 T-cell counts is impaired compared to those who
initiate ART with higher CD4 T-cell counts [37,38]. The
ability to respond to immunisation is also dependant onJournal of Immune Based Therapies and Vaccines 2007, 5:6 http://www.jibtherapies.com/content/5/1/6
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HIV-1-specific IL-4 production and lymphocyte proliferative responses Figure 3
HIV-1-specific IL-4 production and lymphocyte proliferative responses. Significant increases in CT.h4S delta cpm in response to 
HIV-1-specific IL-4 production were seen over the week 17–65 period (A) for groups B (ART + IL-2), C (ART + IL-2 + 
Remune™) and D (ART + Remune™), but not for group A (ART alone) (data not shown). Patient 11 is shown as an example 
of an inverse relationship between lymphocyte proliferative stimulation index (SI) (B) and IL-4 production as delta cpm (C) 
which was evident for 17 of 28 patients who were assessed for IL-4 production.
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Table 1: HLA class I restricted peptides used for IFN-γ ELISpot assays
Peptide Protein Sequence HLA-restriction
Gag
g1 p17 (71–79) GSEELRSLY A1
g2 p17 (77–85) SLYNTVATL A*0201
g3 p17 (20–28) RLRPGGKKK A3
g4 p24 (217–227) ACQGVGGPGHK A11
g5 p17 (84–92) TLYCVHQRI A11
g6 p17 (28–36) KYKLKHIVW A24
g7 p24 (35–43) EVIPMFSAL A26
g8 p24 (16–23) SPRTLNAW B7
g9 p17 (74–82) ELRSLYNTV B8
g10 p24 (197–205) DCKTILKAL B8
g11 p17 (93–101) EIKDTKEAL B8
g12 p17 (24–31) GGKKKKYKL B8
g13 p24 (131–140) KRWIILGLNK B27
g14 p17 (36–44) WASRELERF B35A
g15 p17 (124–132) NSSKVSQNY B35A
g16 p24 (122–130) PPIPVGDIY B35A
g17 p24 (174–184) AEQASQDVKNW B44
g18 p24 (83–92) VHPVHAGPIA B55
g19 p24 (108–117) TSTLQEQIGW B57B
g20 p24 (176–184) QASQEVKNW B57B
g21 p24 (15–23) ISPRTLNAW B57B
g22 p24 (32–40) FSPEVIPMF B57B
g23 p17 (92–101) IEIKDTKEAL B61
Pol
p1 RT (309–317) ILKEPVHGV A*0201
p2 RT (179–187) VIYQYMDDL A2
p3 RT (485–493) ALQDSGLEV A2
p4 RT (341–350) IYQEPFKLNK A11
p5 RT (158–166) AIFQSSMTK A11
p6 IN (179–188) AVFIHNFKRK A11
p7 RT (448–457) RETKLGKAGY A29
p8 RT (392–401) PIQKETWETW A32
p9 RT (18–26) GPKVKQWPL B8
p10 RT (175–183) HPDIVIYQY B35A
p11 RT (156–164) SPAIFQSSM B35A
p12 RT (432–441) EPIVGAETFY B35A
p13 RT (203–212) EELRQHLLRW B44
p14 RT (397–406) TWETWWTEYW B44
Nef
n1 nef (180–189) VLEWRFDSRL A2
n2 nef (73–82) QVPLRPMTYK A11
n3 nef (75–82) PLRPMTYK A11
n4 nef (84–92) AVDLSHFLK A11
n5 nef (128–137) TPGPGVRYPL B7
n6 nef (90–97) FLKEKGGL B8
n7 nef (13–20) WPTVRERM B8
n8 nef (135–143) YPLTFGWCY B18/B49
n10 nef (186–193) DSRLAFHH B35A
n11 nef (74–84) VPLRPMTY B35A
n12 nef (116–125) HTQGYFPDWQ B57B
n13 nef (92–100) KEKGGLEGL B61
Peptides were identified from the NIH HIV Molecular Immunology Database website [50]. References for each peptide are also available at this 
website. RT (reverse transcriptase antigen), IN (integrase antigen). AHLA B35 is associated with rapid progression in HIV-1 infection. BHLA B57 is 
associated with slow/non progression in HIV-1 infectionJournal of Immune Based Therapies and Vaccines 2007, 5:6 http://www.jibtherapies.com/content/5/1/6
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Table 2: Patient HLA types and ELISpot results, showing the sum of delta (background subtracted) IFN-γ spot forming cells (SFC) at 
weeks 0, 16 and 65 for each patient for whom ELISpot analysis was possible.
Patient HLA type (peptides used) Sum of Δ IFN-γ SFC/106 PBMC
Week 0 Week 16 Week 65
Group A Gag Pol Nef Gag Pol Nef Gag Pol Nef
1 A1 (g1)
A2 (g2, p1, p2, p3, n1)
B7 (g8, n2)
B18 (n8)
20 20 260 0 0 150 20 10 680
16 A2, (g2, p1, p2, p3, n1)
B44 (g17, p13, p14)
50 90 110 940 850 320 740 1200 20
36 A2, (g2, p1, p2, p3)
A23, (g13)
B27, (n9)
B49 (n8)
F F F 70 60 30 230 280 370
52 A11, (g4, g5, p5, n2)
A9, (none identified)
B35A, (g14, p10)
B61 (g23, p15, n13)
670 470 295 910 405 1280 370 215 165
54 A2, (g2, p2, n1)
A11, (g5, p5)
B27, (n9)
B35A (g14, p10)
80 190 30 F F F 290 240 160
Group B Gag Pol Nef Gag Pol Nef Gag Pol Nef
7 A2, (g2, p2, p3, n1)
A24, (g6)
B55, (g18)
B57B (g19, g20, 21, g22)
500 30 0 1310 120 20 1340 190 0
35 A3, (g3)
A32, (p8)
B7 (g8, n5)
50 110 75 130 70 25 185 135 115
57 A1, (g1)
B8 (g9, g10, g11, g12, p9, n6, n7)
490 50 130 190 30 20 450 70 120
Group C Gag Pol Nef Gag Pol Nef Gag Pol Nef
4 A1, (g1)
A26, (g7)
B27, (n9)
B57B(g19, g20, g21, g22, n12)
220 nd 50 130 nd 40 520 nd 60
11 A1, (g1)
A2, (g2, p1, p2, p3, n1) B35A, (g14, g15, g16, p10, p11, 
p12, n10, n11)
B57B(g19, g20, g21, g22, n12)
3820 3140 2990 90 50 20 2820 2760 960
14 A1, (g1)
A2, (g2, p1, p2, p3, n1)
B57B,(g19, g20, g21, g22, n12)
B62 (none identified)
F F F 1140 130 20 100 30 70
34 A3, (g3)
A29, (p7)
B35A, (g14, g15, p10, n10)
B44 (g17, p13, p14)
320 100 0 F F F 520 80 10
Group D Gag Pol Nef Gag Pol Nef Gag Pol Nef
13 A2, (g2, p1, p2, n1)
A11, (g4, p4, n2)
B8, (g9, p9, n6)
B62 (none identified)
50 20 70 730 1890 1190 390 640 240
22 A1, (g1)
A2, (g2, p2, n1)
B7, (g8, n5)
B35A (g14, g15, p10, n11)
270 80 120 F F F 60 40 260
F denotes assay failure. IFN-γ (interferon-gamma), PBMC (peripheral blood mononuclear cells), SFC (spot forming cells). AHLA B35 is associated with rapid progression in 
HIV-1 infection. BHLA B57 is associated with slow/non progression in HIV-1 infection.Journal of Immune Based Therapies and Vaccines 2007, 5:6 http://www.jibtherapies.com/content/5/1/6
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higher CD4 T-cell count nadirs and earlier initiation of ART
[39].
The fate of missing HIV-1-specific CD4 T-cell responses is
unclear. HIV-1 preferentially infects and deletes many
HIV-1-specific CD4 T-cells [7], while some remain detect-
able, expressing IFN-γ, though unable to proliferate or
express IL-2 [40,41]. The significant increase in HIV-1-spe-
cific IL-4 production from weeks 17 to 65 in group B
(p24), C (p24) and D (gp120) could indicate clonal dys-
function in these patients. Only group A (ART alone) had
no increase in HIV-1-specific IL-4 production. Thus
immunotherapy in these patients appears to be associated
with increasing levels of HIV-1-specific IL-4 production.
IL-4, an anti-inflammatory type-2 cytokine, has a suppres-
sive effect on lymphocyte proliferation [26,42]. The obser-
vation in a number of patients that HIV-1-specific IL-4
increases when proliferative responses diminish may indi-
cate a mechanism by which clonal proliferation remains
suppressed, although this needs further investigation. We
previously found a balanced IL-4/IL-2 phenotype in HIV-
1-specific CD4 T-cell responses in patients who remain
disease free [27]. While IL-4 expression by HIV-1-specific
CD4 T-cells may be thought of as a pathological anti-pro-
liferative effect, it must be considered that this phenotype
could be protective, by dampening immune activation
and quashing viral replication. This relationship requires
further investigation.
Despite the lack of induced HIV-1-specific T-cell responses
in these patients we report significant increases in recall
antigen proliferative responses, particularly for persistent
antigens. These increases were largely evident between
week 0 and 65 with no differences between groups, sug-
gesting immunotherapy was ineffective in this respect.
While some significant increases in proliferative responses
to HIV-1 antigens were apparent from week 0 to 65 (group
B and D), the same cannot be said regarding the immuno-
therapy period between weeks 17 and 65. Nor were there
any significant differences in responses between groups.
These results suggest that any improvements were singu-
larly attributable to duration of ART.
Of note is one patient in group B, vaccinated with tetanus
4 weeks before receiving IL-2. High tetanus-specific prolif-
eration was enhanced and sustained by subsequent IL-2,
as reported separately [25]. In contrast a second patient
received tetanus vaccination after IL-2 and did not
respond. These responses may be dependent on adminis-
tration of IL-2 subsequent to antigen priming, during T-
cell contraction. Animal models demonstrate IL-2 admin-
istration during T-cell contraction enhances and prolongs
responses, unlike co-administration of IL-2 with antigen
when the survival of responding T cells is abrogated [24].
Our protocol and others that also achieved limited induc-
tion of responses [43] utilized a co-administered model.
Future trials will address such important issues.
We observed low-levels of transient self-limiting viraemia
resulting from IL-2 therapy as previously reported [44].
Despite the lack of detectable cell-mediated responses
induced by immunotherapy in these patients, the tran-
sient viral load blips we have reported appear to occur less
in patients receiving IL-2 when administered with
Remune™ in group C, with a trend towards significance (p
= 0.071). Larger group sizes may have revealed a stronger
relationship between Remune™ and protection from IL-2
induced transient viraemia, but this pilot study was not
powered for such observations. This possible effect of
Remune™ was not due to induction of neutralising anti-
bodies, by the display of potentially sensitive epitopes on
gp41 resulting from the removal of gp120 from Remune™
[45]. We have separately reported the induction of anti-
body responses against HLA-B62 and HLA-DR4 in some
of these patients who received Remune™ immunisation
[46], as Remune™ contains these antigens derived from
the HUT-78 cell line in which it is grown. Group sizes are
too small in this study to determine whether such
responses may have played a role in potential protection
from viral blips in group C.
Conclusion
Combined Remune™ and IL-2 with ART in advanced HIV-
1 infection conferred no immunological benefits to ART.
Taking together the absence of induced HIV-1-specific
lymphocyte proliferative responses, CD8 T-cell IFN-γ
responses and in vivo DTH responses these results imply
that induction of renewed HIV-1-specific cell-mediated
responses by therapeutic immunisation, even when sup-
plemented with IL-2, is extremely problematic in patients
who initiate ART with lower CD4 T-cell counts. Although
a recently reported clinical trial of the vCP1433 canary
pox-based therapeutic vaccine elicited p24-specific
responses which were significantly associated with time
off therapy in a subsequent treatment discontinuation
protocol, these responses also remained transient, dimin-
ishing at study end [47]. This underscores the difficulties
in inducing protective immune responses by therapeutic
immunisation of chronically infected patients. Further-
more immunological protection in chronically infected
individuals may be best conferred by autologous virus, as
opposed to vaccine derived antigens as found with the
vCP1452 canary pox vaccine [48] to which T-cell
responses may in fact be associated with more rapid viral
rebound following treatment interruptions [49]. In our
study we saw the greatest proliferative responses to HIV-1
antigens in patients who experienced virological
rebounds, demonstrating that autologous virus induces
greater responses, albeit transiently, than immunisation
or IL-2 therapy.Journal of Immune Based Therapies and Vaccines 2007, 5:6 http://www.jibtherapies.com/content/5/1/6
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In these chronically infected treated patients, we found
that immunotherapy was associated with increasing HIV-
1-specific IL-4 production, which appears to negatively
impact proliferative responses. HIV-1-specific IL-4 pro-
duction may result from a general dysfunction of HIV-1-
specific CD4 T-cells with pathological implications for
induction of HIV-1-specific responses. We suggest that
these results underscore the importance of early initiation
of ART. As Remune™ may have positive effects in less
advanced patients [17], we suggest further investigations,
with or without cytokine adjuvants, be conducted in
patients for whom extensive immunological damage has
been prevented with earlier initiation of ART.
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